Lung cancer stem cells as a target for therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 2, 2010, Pages 164-171

  Gorelik, Elieser ^a,b,c   Lokshin, Anna ^a,d   Levina, Vera ^a,d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UPMC Shadyside   (United States)

^c Departments of Otolaryngology and Immunology   (United States)

^d Departments of Psychiatry and Medicine   (United States)

Author keywords

Cancer stem cell targeted therapy; Cytokine network; Drug resistance; Human lung cancer stem cells

Indexed keywords

ALDEHYDE DEHYDROGENASE; BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; CANCER GROWTH FACTOR; CD133 ANTIGEN; CD24 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOKERATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR; IMATINIB; INTERLEUKIN 10; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NOTCH RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; RANTES; STAGE SPECIFIC EMBRYO ANTIGEN 3; STAT1 PROTEIN; STEM CELL FACTOR RECEPTOR; TUMOR ANTIGEN; VASCULOTROPIN; WNT PROTEIN;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENIC ACTIVITY; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CYTOKINE PRODUCTION; DNA REPAIR; ENDOTHELIUM CELL; ENZYME ACTIVATION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; MACROPHAGE; MESENCHYME CELL; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SCID MOUSE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STROMA CELL; TARGET CELL; TREATMENT FAILURE; TUMOR CELL; TUMOR GROWTH; XENOGRAFT;

EID: 77950832189     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010790909308     Document Type: Review

References (125)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin., 2009, 59(4), 225-249.
2. Collins, L.G.; Haines, C.; Perkel, R.; Enck, R.E. Lung cancer: diagnosis and management. Am. Fam. Physician, 2007, 75 (1), 56-63.
3. Minna, J.D.; Roth, J.A.; Gazdar, A.F. Focus on lung cancer. Cancer Cell, 2002, 1 (1), 49-52.
4. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414(6859), 105-111.
5. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer, 2005, 5(4), 275-284.
6. Ishii, H.; Iwatsuki, M.; Ieta, K.; Ohta, D.; Haraguchi, N.; Mimori, K.; Mori, M. Cancer stem cells and chemoradiation resistance. Cancer Sci., 2008, 99(10), 1871-1877.
7. Ailles, L.E.; Weissman, I. L. Cancer stem cells in solid tumors. Curr. Opin. Biotechnol., 2007, 18(5), 460-466.
8. Visvader, J.E.; Lindeman, G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer, 2008, 8(10), 755-768.
9. Park, C.Y.; Tseng, D.; Weissman, I.L. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol. Ther., 2009, 17(2), 219-230.
10. Polyak, K.; Haviv, I.; Campbell, I.G. Co-evolution of tumor cells and their microenvironment. Trends Genet., 2009, 25(1), 30-38.
11. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A., 2003, 100(7), 3983-3988. (Pubitemid 36418143)
12. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature, 2004, 432(7015), 396-401.
13. Collins, A.T.; Berry, P.A.; Hyde, C.; Stower, M.J.; Maitland, N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res., 2005, 65(23), 10946-10951.
14. Hermann, P. C.; Huber, S.L.; Herrler, T.; Aicher, A.; Ellwart, J.W.; Guba, M.; Bruns, C.J.; Heeschen, C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 2007, 1 (3), 313-323.
15. Eramo, A.; Lotti, F.; Sette, G.; Pilozzi, E.; Biffoni, M.; Di Virgilio, A.; Conticello, C.; Ruco, L.; Peschle, C.; De Maria, R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ., 2008, 15(3), 504-514.
16. Levina, V.; Marrangoni, A.M.; DeMarco, R.; Gorelik, E.; Lokshin, A.E. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE, 2008, 3(8), e3077.
17. Ricci-Vitiani, L.; Lombardi, D.G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria, R. Identification and expansion of human colon-cancer-initiating cells. Nature, 2007, 445(7123), 111-115.
18. Ignatova, T.N.; Kukekov, V.G.; Laywell, E.D.; Suslov, O.N.; Vrionis, F.D.; Steindler, D.A. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia, 2002, 39(3), 193-206.
19. Dontu, G.; Abdallah, W.M.; Foley, J.M.; Jackson, K.W.; Clarke, M.F.; Kawamura, M.J.; Wicha, M.S. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev., 2003, 17(10), 1253-1270.
20. Miki, J.; Furusato, B.; Li, H.; Gu, Y.; Takahashi, H.; Egawa, S.; Sesterhenn, I.A.; McLeod, D.G.; Srivastava, S.; Rhim, J.S. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumorderived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res., 2007, 67(7), 3153-3161.
21. Vescovi, A.L.; Galli, R.; Reynolds, B.A. Brain tumour stem cells. Nat. Rev. Cancer, 2006, 6(6), 425-436.
22. Ho, M.M.; Ng, A.V.; Lam, S.; Hung, J.Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res., 2007, 67(10), 4827-4833.
23. Zhou, S.; Schuetz, J.D.; Bunting, K.D.; Colapietro, A.M.; Sampath, J.; Morris, J.J.; Lagutina, I.; Grosveld, G.C.; Osawa, M.; Nakauchi, H.; Sorrentino, B.P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med., 2001, 7(9), 1028-1034.
24. Chen, Y.C.; Hsu, H.S.; Chen, Y.W.; Tsai, T.H.; How, C.K.; Wang, C.Y.; Hung, S.C.; Chang, Y.L.; Tsai, M.L.; Lee, Y.Y.; Ku, H.H.; Chiou, S.H. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE, 2008, 3(7), e2637.
25. Ischenko, I.; Seeliger, H.; Schaffer, M.; Jauch, K.W.; Bruns, C.J. Cancer stem cells: how can we target them? Curr. Med. Chem., 2008, 15(30), 3171-3184.
26. Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S.; Schott, A.; Hayes, D.; Birnbaum, D.; Wicha, M.S.; Dontu, G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell. Stem Cell, 2007, 1(5), 555-567.
27. Ucar, D.; Cogle, C.R.; Zucali, J.R.; Ostmark, B.; Scott, E.W.; Zori, R.; Gray, B.A.; Moreb, J.S. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem. Biol. Interact., 2009, 178(1-3), 48-55.
28. Jiang, F.; Qiu, Q.; Khanna, A.; Todd, N.W.; Deepak, J.; Xing, L.; Wang, H.; Liu, Z.; Su, Y.; Stass, S.A.; Katz, R.L. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol. Cancer Res., 2009, 7(3), 330-338.
29. Jiang, T.; Collins, B.J.; Jin, N.; Watkins, D.N.; Brock, M.V.; Matsui, W.; Nelkin, B.D.; Ball, D.W. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res., 2009, 69(3), 845-854.
30. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; Campbell, L.L.; Polyak, K.; Brisken, C.; Yang, J.; Weinberg, R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 2008, 133(4), 704-715.
31. Gupta, G.P.; Massague, J. Cancer metastasis: building a framework. Cell, 2006, 127(4), 679-695.
32. Hung, J.J.; Yang, M.H.; Hsu, H.S.; Hsu, W.H.; Wu, K.J. Prognostic significance of hypoxia-inducible factor-1 alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax, 2009, 64(12), 1082-1089.
33. Zhuo, W.; Wang, Y.; Zhuo, X.; Zhang, Y.; Ao, X.; Chen, Z. Knockdown of Snail, a novel zinc finger transcription factor, via RNA interference increases A549 cell sensitivity to cisplatin via JNK/mitochondrial pathway. Lung Cancer, 2008, 62(1), 8-14.
34. Fidler, I.J.; Hart, I.R. Biological diversity in metastatic neoplasms: origins and implications. Science, 1982, 217(4564), 998-1003.
35. Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer, 2002, 2(8), 563-572.
36. Li, F.; Tiede, B.; Massague, J.; Kang, Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res., 2007, 17(1), 3-14.
37. Schmalhofer, O.; Brabletz, S.; Brabletz, T. E-cadherin, betacatenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev., 2009, 28(1-2), 151-166.
38. Balkwill, F. Cancer and the chemokine network. Nat. Rev. Cancer, 2004, 4(7), 540-550.
39. Orimo, A.; Weinberg, R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle, 2006, 5(15), 1597-1601.
40. Karnoub, A.E.; Dash, A.B.; Vo, A.P.; Sullivan, A.; Brooks, M.W.; Bell, G.W.; Richardson, A.L.; Polyak, K.; Tubo, R.; Weinberg, R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 2007, 449(7162), 557-563.
41. Robinson, S.C.; Coussens, L.M. Soluble mediators of inflammation during tumor development. Adv. Cancer Res., 2005, 93(1), 159-187.
42. Basilico, C.; Moscatelli, D. The FGF family of growth factors and oncogenes. Adv. Cancer Res., 1992, 59(1), 115-165.
43. Etscheid, M.; Beer, N.; Kress, J.A.; Seitz, R.; Dodt, J. Inhibition of bFGF/EGF-dependent endothelial cell proliferation by the hyaluronan-binding protease from human plasma. Eur. J. Cell Biol., 2004, 82(12), 597-604.
44. Seghezzi, G.; Patel, S.; Ren, C.J.; Gualandris, A.; Pintucci, G.; Robbins, E.S.; Shapiro, R.L.; Galloway, A.C.; Rifkin, D.B.; Mignatti, P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol., 1998, 141(7), 1659-1673.
45. Zarnegar, R.; Michalopoulos, G.K. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J. Cell Biol., 1995, 129(5), 1177-1180.
46. Dankbar, B.; Padro, T.; Leo, R.; Feldmann, B.; Kropff, M.; Mesters, R.M.; Serve, H.; Berdel, W.E.; Kienast, J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood, 2000, 95(8), 2630-2636.
47. Axelson, H.; Fredlund, E.; Ovenberger, M.; Landberg, G.; Pahlman, S. Hypoxia-induced dedifferentiation of tumor cells-a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin. Cell Dev. Biol., 2005, 16(4-5), 554-563.
48. Ertmer, A.; Huber, V.; Gilch, S.; Yoshimori, T.; Erfle, V.; Duyster, J.; Elsasser, H.P.; Schatzl, H.M. The anticancer drug imatinib induces cellular autophagy. Leukemia, 2007, 21(5), 936-942.
49. Salgado, R.; Junius, S.; Benoy, I.; Van Dam, P.; Vermeulen, P.; Van Marck, E.; Huget, P.; Dirix, L.Y. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int. J. Cancer, 2003, 103(5), 642-646.
50. Bar-Eli, M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology, 1999, 67(1), 12-18. (Pubitemid 29037606)
51. Fukuyama, T.; Ichiki, Y.; Yamada, S.; Shigematsu, Y.; Baba, T.; Nagata, Y.; Mizukami, M.; Sugaya, M.; Takenoyama, M.; Hanagiri, T.; Sugio, K.; Yasumoto, K. Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Sci., 2007, 98(7), 1048-1054.
52. Henriquet, C.; Gougat, C.; Combes, A.; Lazennec, G.; Mathieu, M. Differential regulation of RANTES and IL-8 expression in lung adenocarcinoma cells. Lung Cancer, 2007, 56(2), 167-174.
53. Luppi, F.; Longo, A.M.; de Boer, W.I.; Rabe, K.F.; Hiemstra, P.S. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer, 2007, 56(1), 25-33.
54. Salcedo, R.; Oppenheim, J.J. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation, 2003, 10(3-4), 359-370.
55. Stathopoulos, G.T.; Psallidas, I.; Moustaki, A.; Moschos, C.; Kollintza, A.; Karabela, S.; Porfyridis, I.; Vassiliou, S.; Karatza, M.; Zhou, Z.; Joo, M.; Blackwell, T.S.; Roussos, C.; Graf, D.; Kalomenidis, I. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J. Natl. Cancer Inst., 2008, 100(20), 1464-1476.
56. Nokihara, H.; Nishioka, Y.; Yano, S.; Mukaida, N.; Matsushima, K.; Tsuruo, T.; Sone, S. Monocyte chemoattractant protein-1 gene modification of multidrug-resistant human lung cancer enhances antimetastatic effect of therapy with anti-P-glycoprotein antibody in SCID mice. Int. J. Cancer, 1999, 80(5), 773-780. (Pubitemid 29066292)
57. Ben-Baruch, A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev., 2006, 25(3), 357-371.
58. Strieter, R.M.; Belperio, J.A.; Phillips, R.J.; Keane, M.P. Chemokines: angiogenesis and metastases in lung cancer. Novartis Found Symp., 2004, 256(1), 173-184.
59. Gorelik, L.; Flavell, R.A. Transforming growth factor-beta in Tcell biology. Nat. Rev. Immunol., 2002, 2(1), 46-53.
60. Salazar-Onfray, F. Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med. Oncol., 1999, 16(2), 86-94.
61. Salgado, R.; Benoy, I.; Bogers, J.; Weytjens, R.; Vermeulen, P.; Dirix, L.; Van Marck, E. Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis, 2001, 4(1), 37-43.
62. Enewold, L.; Mechanic, L.E.; Bowman, E.D.; Zheng, Y.L.; Yu, Z.; Trivers, G.; Alberg, A.J.; Harris, C.C. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol. Biomarkers Prev., 2009, 18(1), 215-222.
63. Hartsell, W.F.; Scott, C.B.; Dundas, G.S.; Mohiuddin, M.; Meredith, R.F.; Rubin, P.; Weigensberg, I.J. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03. Am. J. Clin. Oncol., 2007, 30(4), 368-376.
64. Songur, N.; Kuru, B.; Kalkan, F.; Ozdilekcan, C.; Cakmak, H.; Hizel, N. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori, 2004, 90(2), 196-200.
65. Levina, V.; Su, Y.; Nolen, B.; Liu, X.; Gordin, Y.; Lee, M.; Lokshin, A.; Gorelik, E. Chemotherapeutic drugs and human tumor cells cytokine network. Int. J. Cancer, 2008, 123(9), 2031-2040.
66. Keedy, V.L.; Sandler, A.B. Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci., 2007, 98(12), 1825-1830.
67. Sandler, A.; Gray, R.; Perry, M. C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilenbaum, R.; Johnson, D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med., 2006, 355(24), 2542-12450
68. Lynch, T.J.; Blumenschein, G.R.; Engelman, J.A.; Espinoza-Delgado, I.; Govindan, R.; Hanke, J.; Hanna, N.H.; Heymach, J.V.; Hirsch, F.R.; Janne, P.A.; Lilenbaum, R.C.; Natale, R.B.; Riely, G.J.; Sequist, L.V.; Shapiro, G.I.; Shaw, A.; Shepherd, F.A.; Socinski, M.; Sorensen, A.G.; Wakelee, H.A.; Weitzman, A. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J. Thorac. Oncol., 2008, 3(6), 107-112.
69. Horn, L.; Sandler, A.B. Angiogenesis in the treatment of non-small cell lung cancer. Proc. Am. Thorac. Soc., 2009, 6(2), 206-217.
70. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344(14), 1031-1037.
71. Ben-Porath, I.; Thomson, M.W.; Carey, V.J.; Ge, R.; Bell, G.W.; Regev, A.; Weinberg, R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet., 2008, 40(5), 499-507.
72. Zhang, X.; Crespo, A.; Fernandez, A. Turning promiscuous kinase inhibitors into safer drugs. Trends Biotechnol., 2008, 26(6), 295-301.
73. Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer, 2009, 9(1), 28-39.
74. Daniel, V.C.; Peacock, C.D.; Watkins, D. N. Developmental signalling pathways in lung cancer. Respirology, 2006, 11(3), 234-240.
75. Peacock, C.D.; Watkins, D.N. Cancer stem cells and the ontogeny of lung cancer. J. Clin. Oncol., 2008, 26(17), 2883-2889.
76. Perez-Tomas, R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem., 2006, 13(16), 1859-1876.
77. Alison, M.R.; Lebrenne, A.C.; Islam, S. Stem cells and lung cancer: future therapeutic targets? Expert Opin. Biol. Ther., 2009, 9(9), 1127-1141.
78. Levina, V.; Marrangoni, A.M.; Wang, T.; Parikh, S.; Su, Y.; Herberman, R.B.; Lokshin, A.; Gorelik, E. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res., 2010, 70(1), 338-346.
79. Zou, Y.R.; Kottmann, A.H.; Kuroda, M.; Taniuchi, I.; Littman, D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature, 1998, 393(6685), 595-599.
80. Zhou, Y.; Larsen, P.H.; Hao, C.; Yong, V.W. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J. Biol. Chem., 2002, 277(51), 49481-49487.
81. Miller, R. J.; Banisadr, G.; Bhattacharyya, B. J. CXCR4 signaling in the regulation of stem cell migration and development. J. Neuroimmunol., 2008, 198(1-2), 31-38.
82. Otsuka, S.; Bebb, G. The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer. J. Thorac. Oncol., 2008, 3(12), 1379-1383.
83. Sugiyama, T.; Kohara, H.; Noda, M.; Nagasawa, T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity, 2006, 25(6), 977-988.
84. Kato, M.; Kitayama, J.; Kazama, S.; Nagawa, H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res., 2003, 5(5), 144-150.
85. Su, L.; Zhang, J.; Xu, H.; Wang, Y.; Chu, Y.; Liu, R.; Xiong, S. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin. Cancer Res., 2005, 11(23), 8273-8280.
86. Muller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M.E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S. N.; Barrera, J.L.; Mohar, A.; Verastegui, E.; Zlotnik, A. Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001, 410(6824), 50-56.
87. Phillips, R.J.; Burdick, M.D.; Lutz, M.; Belperio, J.A.; Keane, M.P.; Strieter, R.M. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am. J. Respir. Crit. Care Med., 2003, 167(12), 1676-1686.
88. Ceradini, D.J.; Kulkarni, A.R.; Callaghan, M.J.; Tepper, O.M.; Bastidas, N.; Kleinman, M.E.; Capla, J.M.; Galiano, R.D.; Levine, J.P.; Gurtner, G.C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med., 2004, 10(8), 858-864.
89. Burger, J.A.; Stewart, D.J. CXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opin. Investig. Drugs, 2009, 18(4), 481-490.
90. Flomenberg, N.; DiPersio, J.; Calandra, G. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol., 2005, 114(4), 198-205.
91. DiPersio, J.F.; Uy, G.L.; Yasothan, U.; Kirkpatrick, P. Plerixafor. Nat. Rev. Drug Discov., 2009, 8(2), 105-106.
92. Wong, D.; Korz, W. Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside. Clin. Cancer Res., 2008, 14(24), 7975-7980.
93. Richert, M.M.; Vaidya, K.S.; Mills, C.N.; Wong, D.; Korz, W.; Hurst, D.R.; Welch, D.R. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol. Rep., 2009, 21(3), 761-767.
94. Porvasnik, S.; Sakamoto, N.; Kusmartsev, S.; Eruslanov, E.; Kim, W.J.; Cao, W.; Urbanek, C.; Wong, D.; Goodison, S.; Rosser, C.J. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate, 2009, 69(13), 1460-1469.
95. Kwong, J.; Kulbe, H.; Wong, D.; Chakravarty, P.; Balkwill, F. An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol. Cancer Ther., 2009, 8(7), 1893-1905.
96. Zsebo, K.M.; Williams, D.A.; Geissler, E.N.; Broudy, V.C.; Martin, F.H.; Atkins, H.L.; Hsu, R.Y.; Birkett, N.C.; Okino, K.H.; Murdock, D.C. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell, 1990, 63(1), 213-224.
97. Williams, D.E.; de Vries, P.; Namen, A.E.; Widmer, M.B.; Lyman, S.D. The steel factor. Dev. Biol., 1992, 151(2), 368-376.
98. Dolci, S.; Williams, D.E.; Ernst, M.K.; Resnick, J.L.; Brannan, C.I.; Lock, L.F.; Lyman, S.D.; Boswell, H.S.; Donovan, P.J. Requirement for mast cell growth factor for primordial germ cell survival in culture. Nature, 1991, 352(6338), 809-811.
99. Broudy, V.C. Stem cell factor and hematopoiesis. Blood, 1997, 90(4), 1345-1364.
100. Anzai, H.; Nagayoshi, M.; Obata, M.; Ikawa, Y.; Atsumi, T. Selfrenewal and differentiation of a basic fibroblast growth factordependent multipotent hematopoietic cell line derived from embryonic stem cells. Dev. Growth Differ., 1999, 41(1), 51-58.
101. Yarden, Y.; Kuang, W. J.; Yang-Feng, T.; Coussens, L.; Munemitsu, S.; Dull, T. J.; Chen, E.; Schlessinger, J.; Francke, U.; Ullrich, A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J., 1987, 6(11), 3341-3351.
102. Duronio, V.; Welham, M.J.; Abraham, S.; Dryden, P.; Schrader, J.W. P21ras activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21ras GTPase-activating protein. Proc. Natl. Acad. Sci. U.S.A., 1992, 89(5), 1587-1591.
103. Serve, H.; Hsu, Y.C.; Besmer, P. Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. J. Biol. Chem., 1994, 269(8), 6026-6030.
104. Linnekin, D.; DeBerry, C.S.; Mou, S. Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J. Biol. Chem., 1997, 272(43), 27450-27455.
105. Sattler, M.; Salgia, R.; Shrikhande, G.; Verma, S.; Pisick, E.; Prasad, K.V.; Griffin, J.D. Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing ckit, phosphatidylinositol 3-kinase, and p120(CBL). J. Biol. Chem., 1997, 272(15), 10248-10253.
106. Edling, C.E.; Hallberg, B. c-Kit--a hematopoietic cell essential receptor tyrosine kinase. Int. J. Biochem. Cell Biol., 2007, 39(11), 1995-1998.
107. Timeus, F.; Crescenzio, N.; Valle, P.; Pistamiglio, P.; Piglione, M.; Garelli, E.; Ricotti, E.; Rocchi, P.; Strippoli, P.; Cordero di Montezemolo, L.; Madon, E.; Ramenghi, U.; Basso, G. Stem cell factor suppresses apoptosis in neuroblastoma cell lines. Exp. Hematol., 1997, 25(12), 1253-1260.
108. Krystal, G.W.; Hines, S.J.; Organ, C.P. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res., 1996, 56(2), 370-376.
109. Hines, S.J.; Organ, C.; Kornstein, M.J.; Krystal, G.W. Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ., 1995, 6(6), 769-779.
110. Yasuda, A.; Sawai, H.; Takahashi, H.; Ochi, N.; Matsuo, Y.; Funahashi, H.; Sato, M.; Okada, Y.; Takeyama, H.; Manabe, T. Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway. Dig. Dis. Sci., 2007, 52(9), 2292-2300.
111. Kindler, T.; Breitenbuecher, F.; Marx, A.; Beck, J.; Hess, G.; Weinkauf, B.; Duyster, J.; Peschel, C.; Kirkpatrick, C.J.; Theobald, M.; Gschaidmeier, H.; Huber, C.; Fischer, T. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood, 2004, 103(10), 3644-3654.
112. Joensuu, H. Sunitinib for imatinib-resistant GIST. Lancet, 2006, 368(9544), 1303-1304.
113. Lennartsson, J.; Ronnstrand, L. The stem cell factor receptor/c-Kit as a drug target in cancer. Curr. Cancer Drug Targets, 2006, 6(1), 65-75.
114. Yaren, A.; Oztop, I.; Kargi, A.; Ulukus, C.; Onen, A.; Sanli, A.; Binicier, O.; Yilmaz, U.; Alakavuklar, M. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. Int. J. Clin. Pract., 2006, 60(6), 675-682.
115. Hassan, H. T. c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications. Leuk. Res., 2009, 33(1), 5-10.
116. Micke, P.; Basrai, M.; Faldum, A.; Bittinger, F.; Ronnstrand, L.; Blaukat, A.; Beeh, K. M.; Oesch, F.; Fischer, B.; Buhl, R.; Hengstler, J. G. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin. Cancer Res., 2003, 9(1), 188-194.
117. Butnor, K.J.; Burchette, J.L.; Sporn, T.A.; Hammar, S.P.; Roggli, V.L. The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature. Arch. Pathol. Lab. Med., 2004, 128(5), 538-543.
118. Micke, P.; Hengstler, J.G.; Albrecht, H.; Faldum, A.; Bittinger, F.; Becker, K.; Wiewrodt, R.; Fischer, B.; Buhl, R. c-kit expression in adenocarcinomas of the lung. Tumour Biol, 2004, 25(5-6), 235-242.
119. Pietsch, T.; Nicotra, M.R.; Fraioli, R.; Wolf, H.K.; Mottolese, M.; Natali, P.G. Expression of the c-Kit receptor and its ligand SCF in non-small-cell lung carcinomas. Int J. Cancer, 1998, 75(2), 171-175.
120. Heinrich, M.C.; Corless, C.L.; Blanke, C.D.; Demetri, G.D.; Joensuu, H.; Roberts, P.J.; Eisenberg, B.L.; von Mehren, M.; Fletcher, C.D.; Sandau, K.; McDougall, K.; Ou, W.B.; Chen, C.J.; Fletcher, J.A. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol., 2006, 24(29), 4764-4774.
121. Druker, B.J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G.M.; Fanning, S.; Zimmermann, J.; Lydon, N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 1996, 2(5), 561-566.
122. Rubin, B.P.; Duensing, A. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab. Invest., 2006, 86(10), 981-986.
123. Buschbeck, M. Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer. Drugs R.D., 2006, 7(2), 73-86.
124. Kerkela, R.; Grazette, L.; Yacobi, R.; Iliescu, C.; Patten, R.; Beahm, C.; Walters, B.; Shevtsov, S.; Pesant, S.; Clubb, F.J.; Rosenzweig, A.; Salomon, R.N.; Van Etten, R.A.; Alroy, J.; Durand, J.B.; Force, T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med., 2006, 12(8), 908-916.
125. Gupta, P.B.; Chaffer, C.L.; Weinberg, R.A. Cancer stem cells: mirage or reality? Nat. Med., 2009, 15(9), 1010-1012.